NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,011 DKK | +0.84% |
|
+2.24% | +44.68% |
| 12:42pm | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
| 09:22am | NOVO NORDISK : UBS gives a Neutral rating | ZD |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,003
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.88% | 638B | |
| +56.31% | 819B | |
| -6.53% | 351B | |
| +19.85% | 329B | |
| +9.56% | 298B | |
| +17.28% | 242B | |
| +2.25% | 225B | |
| +13.36% | 217B | |
| +9.57% | 168B | |
| -2.74% | 158B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Sector Update: Health Care
